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Incubation of primary cultures of hepatocytes from fed and fasted rats with calcium ionophore strongly decreased glucose production from 
pyruvate. Like insulin, calcium ionophore A23187, phenylephrine, vasopressin, and prostaglandins E, and F, caused a significant reduction 
(S&60%) in basal concentrations of mRNA for P-enolpyruvate carboxykinase (PEPCK), the main regulatory enzyme of gluconeogenesis. Phenyl- 
ephrine, prostaglandin E, and calcium ionophore A231 87 were also able to counteract he induction of PEPCK gene expression by Bt,cAMP. These 
effects were similar to those exerted by both vanadate and phorbol ester TPA. The decrease in extracellular calcium by the addition of the 
calcium-chelating agent EGTA to the incubation medium caused an increase in PEPCK mRNA levels. This effect was additive to that of Bt,cAMP 
and was counteracted by vanadate. 
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1. INTRODUCTION 
Hormones that act via changes in intracellular Ca2+ 
levels (adrenergic agonists, vasopressin, prostaglandins, 
etc.) interact with their own specific plasma membrane 
receptors to generate two intracellular messengers, 
myoinositol-1,4,5triphosphate (IP,) and 1,2-diacylglyc- 
erol [l]. Diacylglycerol has been shown specifically to 
activate protein kinase C in a calcium-dependent man- 
ner [2], whereas IP3 mediates the release of free Ca2+ 
from specific intracellular pools [3]. However, calcium 
release accounts for only part of the overall rise induced 
in cytosolic Ca2+, an important part originating from 
Ca2’ influx through the plasma membrane [4]. The rise 
in cytosolic Ca’+, in combination with calmodulin and/ 
or other effecters, leads to the activation of a number 
of Ca2’-linked protein kinases, including Ca2+/calmod- 
ulin-dependent protein kinases, phosphorylase kinase 
and protein kinase C [5-71. These enzymes catalyze the 
phosphorylation of a number of protein substrates that 
cause changes in gluconeogenic and glycolytic flux [8]. 
While much is known about the short-term mechanisms 
by which calcium controls cytosolic processes, little has 
been reported about the long-term mechanisms by 
which calcium regulates glucose metabolism and gene 
expression. 
The cytosolic form of P-enolpyruvate carboxykinase 
(PEPCK), which catalyzes the rate-limiting conversion 
of oxalacetate to phosphoenolpyruvate in hepatic glu- 
coneogenesis, is regulated by changes in the transcrip- 
tion rate of its gene [9]. Glucocorticoids and CAMP 
increase PEPCK gene expression, whereas insulin and 
TPA have the opposite effect [l&18]. Like phorbol ester 
TPA, the synthetic diacylglycerol sn-1 ,Zdioctanoylglyc- 
erol also inhibits PEPCK gene transcription, indicating 
that the stimulation of protein kinase C results in a 
decrease in PEPCK gene expression [ 111. Although both 
TPA and insulin repress PEPCK gene transcription 
through different pathways [11,14,19], they share a 
common DNA element [14,191. Vanadate is also able to 
inhibit PEPCK gene expression both in cultured 
hepatoma cells [20] and ‘in vivo’ in diabetic animals [21]. 
We have previously shown sequences responsive to va- 
nadate between sites -109 and -68 in the 5’-flanking 
region of the PEPCK gene [20]. The most likely target 
for vanadate in this region is the CAMP-responsive ele- 
ment (CRE), which maps from -91 to -84 [20]. This 
would indicate a major difference in the site of action 
of vanadate and insulin, since an insulin-responsive le- 
ment has been located between -416 and -407 on the 
PEPCK promoter [19]. Vanadate and insulin may initi- 
ate a common signal, for example, via phosphorylation 
of the insulin receptor, since vanadate inhibits 
phosphotyrosine phosphatases [22,23]. Vanadate has 
other effects, e.g. it increases the formation of inositol 
phosphates [24] and the uptake of Ca2’ [25], which 
could further alter the transcription of the PEPCK gene. 
Recently, it has been suggested that calcium may medi- 
ate the regulation of gene expression by insulin [26]. 
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ing agents on glucose production and PEPCK gene ex- 
pression in rat hepatocytes in primary culture, in com- 
parison with the effects of insulin, phorbol ester TPA 
and vanadate. We found that calcium-mobilizing agents 
inhibit basal and Bt,cAMP-induced PEPCK gene ex- 
pression, suggesting that the activation of calcium/cal- 
modulin-dependent protein kinases could be involved in 
this process. 
2. MATERIALS AND METHODS 
2.1. Materials 
The random-primed DNA labeling kit and Bt,cAMP were obtained 
from Boehringer Mannheim. [“P]dCTP (3000 Ci/mmol) came from 
Amersham Corp. GeneScreen Plus was obtained from DuPont-New 
England Nuclear. All media and sera were obtained from Gibco Lab- 
oratories. TPA, vasopressin, phenylephrine, prostaglandins and cal- 
cium ionophore A23187 came from Sigma. Insulin was obtained from 
Calbiochem. The other reagents used were of the highest purity avail- 
able. P-enolpyruvate carboxykinase cDNA was a gift from Dr. Rich- 
ard W. Hanson, Case Western Reserve University, Cleveland, Ohio, 
USA. Tyrosine aminotransferase (TAT) cDNA was obtained from 
Dr. Giinter Schlitz, Institute of Cell and Tumor Biology, German 
Cancer Research Center, Heidelberg, Germany. 
2.2. Preparation and incubation of hepatocytes 
Male Sprague-Dawley rats, weighing 20&250 g were used in these 
studies. They were fed ‘at libitum’ unless otherwise indicated. Hepato- 
cytes were isolated as previously described [27]. After removal of 
non-parenchymal cells and debris, hepatocytes were resuspended in 
Dulbecco’s minimal essential medium (DMEM) containing 0.2% al- 
bumin and 10% fetal calf serum. 5.5 x lo6 cells were plated in 10 ml 
of this medium on collagen-coated ishes and maintained at 37°C 
under a CO, atmosphere. Four hours later, medium was removed and 
replaced by 10 ml of fresh DMEM medium containing 0.2% albumin 
without fetal calf serum. Hepatocytes were maintained in this medium 
for 1618 h before treatment with different effecters. Then, cells were 
incubated with medium (no serum or hormones added) or with 50 nM 
insulin, 10 PM phenylephrine, 100 nM vasopressin, 25 PM prosta- 
glandin EZ, 20 FM prostaglandin F,, 5 PM calcium ionophore 
A23187, 0.5 mM Bt,cAMP plus 1 mM theophylline, 1 PM phorbol 
ester TPA, 1 mM vanadate, or with different combinations of the 
effecters. The concentration of EGTA used in individual experiments 
is indicated in the text. 
2.3. Isolation and analysis of cellular RNA 
Total RNA was extracted from primary cultures of hepatocytes and 
from tissues by the guanidine isothiocyanate method [28], and RNA 
samples (20 pg) were electrophoresed on a 1% agarose gel containing 
2.2 M formaldehyde. Northern blots were hybridized to “P-labeled 
cDNAs. The PEPCK cDNA probe corresponded to a 1.1 kb PstILPstI 
fragment from the 3’ end of the PEPCK cDNA [29]; the tyrosine 
aminotransferase (TAT) cDNA probe corresponded to a 600 bp PstI- 
PstI fragment which included the 3’ end of the tyrosine aminotrans- 
ferase cDNA [30]; the /I-actin probe corresponded to a 1.3 kb EcoRII 
EcoRI fragment of /I-actin cDNA [31]. These probes were labeled 
using [cc-“P]dCTP, following the method of random oligopriming as 
described by the manufacturer. Specific activity of the DNA probe 
labelled in this manner was approximately lo9 cpm/pg DNA. Mem- 
branes were placed in contact with Kodak XAR-5 film, and densitom- 
etric analysis of autoradiograms was performed at non-saturating 
exposures with a scanning densitometer. The actin signal was used to 
correct for loading inequalities. Presentation of the data and statistical 
analysis were performed as indicated previously [32]. Differences were 
considered statistically significant at P < 0.05. 
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3. RESULTS 
3.1. Effects of calcium-mobilizing agents on the rate of 
gluconeogenesis byhepatocytes in primary culture 
Primary cultures of hepatocytes isolated from fed and 
48-h starved rats were incubated for up to 24 h in 
DMEM without glucose and supplemented with 20 mM 
pyruvate as a gluconeogenic precursor, with or without 
calcium ionophore A23187, prostaglandin E2, or the 
combination of both effecters. An aliquot of the incuba- 
tion medium was removed at different times, and glu- 
cose production was measured. Both calcium ionophore 
and prostaglandin E, inhibited glucose production in 
hepatocytes from fed (80% and 25% reduction, respec- 
tively, at 24 h), and from starved, rats (80% and 40% 
reduction, respectively, at 24 h) (Fig. 1A and B). When 
both effecters were added together, 90% inhibition of 
glucose production was detected. These results indicate 
that calcium-mobilizing agents are able to inhibit glu- 
coneogenesis by hepatocytes in primary culture. 
3.2. Effects of calcium-mobilizing agents on PEPCK 
gene expression 
PEPCK is the main regulatory enzyme of glu- 
coneogenesis, and its activity is regulated at the level of 
expression of the gene [9]. The effects of hormones that 
act via changes in intracellular calcium levels on the 
regulation of the PEPCK mRNA levels were studied in 
rat hepatocytes in primary culture. Effecters belonging 
to different groups (catecholamines, peptides and pro- 
staglandins) were used, but all raise cytosolic calcium 
levels when added to the incubation medium of liver 
parenchymal cells [ 11. Treatment of hepatocytes for 4 h 
with calcium ionophore A23 187, phenylephrine, vaso- 
pressin, prostaglandins E2 and Fti led to a decrease in 
PEPCK mRNA levels (50-60% reduction), as deter- 
mined by Northern blotting (Fig. 2A). This effect was 
similar to that noted following treatment of hepatocytes 
with insulin (Fig. 2A). We also investigated whether the 
expression of the gene for tyrosine aminotransferase 
(TAT), which is related to gluconeogenesis and regu- 
lated in a manner similar to PEPCK [33-351, was mod- 
ified by these hormones. Like for PEPCK, TAT mRNA 
levels were decreased by treatment of hepatocytes with 
the different calcium-mobilizing agents used (Fig. 2B). 
Incubation of hepatocytes with Bt,cAMP plus theo- 
phylline increased the level of PEPCK mRNA (17-fold), 
while phenylephrine, prostaglandin E, and calcium 
ionophore A23187 blocked this induction (40-50% re- 
duction) (Fig. 3). The effect of insulin was slightly 
stronger than that of the calcium-mobilizing agents and 
caused a 60% reduction of the Bt,cAMP-induced 
PEPCK mRNA levels (Fig. 3). 
Phorbol ester TPA and vanadate also decreased 
PEPCK mRNA levels induced by Bt,cAMP in primary 
culture of rat hepatocytes (Fig. 4A). The inhibitory ef- 
fect of these two effecters was additive, and hepatocytes 
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Fig. 1. Effects of the calcium ionophore A23187 and prostaglandin Ez on glucose production from pyruvate in hepatocytes in primary culture. 
Hepatocytes in primary culture, isolated from fed (A) and 24-h fasted rats (B), were incubated in a medium with 20 mM pyruvate and lacking 
glucose, in the absence (0) or presence of 5 PM calcium ionophore A23187 (Y), 25 PM prostaglandin Ez (v), or combinations of both effecters 
(0). At the indicated time, glucose concentration was measured in the incubation medium of the cells as indicated in section 2. The results are mean 
f S.E.M. of four different experiments. 
cultured in the presence of TPA plus vanadate com- 
pletely blocked PEPCK gene expression, in contrast to 
hepatocytes treated with the effecters alone, which only 
showed 70% reduction (Fig. 4A). However, overnight 
pretreatment of hepatocytes with I ,uM TPA, which 
downregulates protein kinase C [36], did not modify the 
effect of vanadate on PEPCK mRNA levels (Fig. 4A). 
We have already demonstrated that further addition of 
the phorbol ester to TPA-pretreated hepatocytes does 
not cause any significant reduction on Bt,cAMP-in- 
duced PEPCK mRNA levels [32]. Similar effects of va- 
nadate and TPA were noted on TAT mRNA concentra- 
tion (Fig. 4B). These results suggest he mechanism of 
inactivation of PEPCK gene expression by vanadate is 
different from that of TPA, and that protein kinase C 
is probably not involved in vanadate action. 
3.3. Effect of calcium-chelating a ent EGTA on PEPCK 
gene expression 
Since the action of agents that increase the cytosolic 
calcium concentration resulted in inhibition of the 
PEPCK gene expression, we next investigated whether 
a decrease in extracellular calcium could modify the 
expression of this gene. Incubation of hepatocytes in 
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Fig. 2. Effects of calcium-mobilizing agents on PEPCK and TAT mRNA levels. Hepatocytes in primary culture were incubated with a medium 
(no serum or hormones added) (Con), 50 nM insulin (Ins), 1OpM phenylephrine (Phe), 100 nM vasopressin (Vas), 5 PM calcium ionophore A23187 
(A23187), 25 ,uM prostaglandin Ez (PGEJ and 20pM prostaglandin F, (PGF,) for 4 h. RNA was extracted from the cells, and the concentration 
of PEPCK (A) and TAT (B) mRNA was determined by Northern blotting using PEPCK and TAT cDNAs as hyb~d~ation probes. The data are 
expressed as a percentage of non-treated control c&s, and results are mean ?r S.E.M. of three independent experiments. 
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Fig. 3. Effects of calcium-mobilizing agents on Bt,cAMP induced PEPCK mRNA levels. The level of RNA for PEPCK was determined by Northern 
analysis of total RNA isolated from hepatocytes treated for 4 h with 0.5 mM B&AMP plus 1 mM ~~phylline (CAMP) and with combinations 
of 0.5 mM BYAMP plus 1 mM theophylhne and 10 PM phenylephrine (Phe), 5 ,uM calcium ionophore A23187,25 ,uM prostaglandin E, (PGE,) 
and 50 nM insulin (Ins). The data are expressed as a percentage of non-treated control cells, and results are mean + S.E.M. of three independent 
experiments. A representative Northern blot is presented. 
primary culture in DMEM with increasing concentra- 
tions of the calcium-chelating agent EGTA for 4 h led 
to an increase of PEPCK mRNA levels (Fig. 5A). This 
effect was detected at concentrations of EGTA of 2.5 
mM or greater. At 1 mM EGTA no effect on PEPCK 
mRNA levels was noted, probably due to an inadequate 
reduction of the free unchelated calcium content of the 
incubation medium. A similar effect was noted when 
TAT mRNA levels were analyzed (Fig. 5B). The induc- 
tion of TAT gene expression was even higher than that 
observed on PEPCK The effect of 4 mM EGTA was 
also time-dependent (Fig. SC and D). Hepatocytes incu- 
bated with 4 mM EGTA for different periods of time 
showed an increase in PEPCK mRNA levels, which was 
maximal after 2 h of incubation (Fig. 5C). Like for 
PEPCK, TAT mRNA levels also increased, but the 
maximal effect was noted after 4 h of incubation (Fig. 
5D). These results suggest hat the presence of calcium 
in the incubation medium maintains the expression rate 
of PEPCK and TAT low, since when extracellular levels 
of the cation are decreased, an induction of the mRNA 
concentration of both genes is detected. Thus calcium/ 
calmodulin protein kinases may have a role in blocking 
the expression of these genes. 
The effect of EGTA on PEPCK gene expression was 
additive to the induction provoked by Bt,cAMP when 
cells were incubated with both effecters together for 2 
h (Fig. 6), indicating that the decrease in extracellular 
calcium favours the CAMP-mediated induction of 
PEPCK gene expression. Vanadate was able to inhibit 
both the induction caused by EGTA alone and that 
caused by the combination of EGTA and B&CAMP 
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Fig. 4. Effects of combinations of vanadate and TPA on PEPCK and 
TAT mRNA levels. Hepatocytes were treated for 4 h with combina- 
tions of 0.5 mM Bt,cAMP plus 1 mM theophylline (CAMP), 1 mM 
vanadate (Van) and/or 1 PM TPA. In addition, cells were pretreated 
for 18 h with 1 PM TPA (+ TPA O/N) and then treated for 4 additional 
hours with the combination of 0.5 mM B&CAMP and i mM vanadate. 
The levels of PEPCK (A) and TAT (B) mRNA were determined by 
Northern analysis using RNA isolated from the hepatocytes. Data are 
expressed as a percentage of CAMP induction. Results represent he 
mean f S.E.M. of three inde~ndent experiments. A repre~n~tive 
Northern blot is presented. Lanes: 1, control; 2, CAMP; 3, 
CAMP + Van; 4, CAMP + TPA; 5, CAMP + Van + TPA; 6, TPA 
O/N + CAMP + Van. 
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Fig. 5. Effect of the calcium chelating agent EGTA on PEPCK and TAT gene expression. Panel A and B, show the effect of 4 h treatment with 
increasing concentrations of EGTA on PEPCK and TAT mRNA levels in hepatocytes in primary culture. Panel C and D, indicate time-dependent 
effects of 4 mM EGTA on PEPCK and TAT mRNA Ievels. RNA was extracted from the cells, and the con~ntmtion of PEPCK and TAT mRNA 
was determined by Northern blotting using PEPCK and TAT cDNAs as hyb~~~tion probes. The data are expressed as a percentage of non-treated 
control cells. Results are mean k S.E.M. of four independent experiments. A representative Northern blot is presented. 
(Fig. 6). Similar effects were observed in FTO-2B rat 
hepatoma cells treated with these effecters (data not 
shown). These results suggest hat vanadate could coun- 
teract the EGTA effect either by releasing calcium from 
intracellular stores or through a mechanism independ- 
ent of the cation. 
4. DISCUSSION 
Intracellular calcium causes a wide variety of effects 
in cellular processes. In the present study, we show that 
calcium-mobilizing agents are able to inhibit glu- 
coneogenesis, at least in part by reducing the amount of 
PEPCK and TAT in rat hepatocytes in primary culture. 
In addition, they are able to counteract he induction of 
the mRNA concentration of these genes by Bt,cAMP 
This effect is simiiar to that described for insulin. Insu- 
lin and TPA block PEPCK gene transcription through 
different pathways, since preincubation of hepatoma 
cells with phorbol esters, which down-regulates protein 
kinase C, does not affect the inhibitory action of insulin 
on the PEPCK gene, while it attenuates the TPA-inhibi- 
tion of PEPCK gene expression [11,19,38]. However, 
both insulin and TPA share a common DNA element 
in the PEPCK promoter [ 191. On the other hand, 
changes in cytosolic calcium concentration can alter the 
induction of the p33 gene transcription caused by either 
insulin or calcium ionophore A23187 [26], suggesting 
CAMP - + - - + + - + 
EGTA - - f - + - + + 
Van -_-+_+++ 
Fig. 6. Effect of combination of EGTA and Bt,cAMP on PEPCK 
mRNA levels. Hepatocytes in primary culture were incubated with 
medium (no hormones or serum added), or with 0.5 mM BYAMP 
plus 1 mM ~eophylline (CAMP), 4 mM EGTA, 1 mM vanadate (Van) 
and with combinations of these effecters for 2 h. The levels of RNA 
for PEPCK were determined by Northern analysis. The data are 
presented as fold induction with respect to the control non-treated 
cells. Results are mean + S.E.M. of four independent experiments. 
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that calcium might exert an important role in mediating 
insulin’s regulation of gene expression. Our study also 
shows that vanadate, an insulin mimetic agent that in- 
creases the phosphorylation of the insulin receptor by 
inhibition of phosphotyrosine phosphatases, inactivates 
PEPCK gene expression through a mechanism that is 
independent of protein kinase C. Intracellular calcium 
concentration might be involved in the action of vana- 
date, since this effector is able to increase the uptake of 
calcium [25] and increase the formation of inositol phos- 
phates [24]. We have shown that the effects of vanadate 
on glycogen phosphorylase activity in isolated hepato- 
cytes are dependent on calcium in the medium, while the 
inactivation by vanadate of glycogen synthase is inde- 
pendent of the presence of the cation [37]. Similarly, the 
epidermal growth factor (EGF) causes the activation of 
the EGF receptor tyrosine kinase, which results in an 
induction of calcium influx in many cell types [3840]. 
EGF is able to induce the expression of several genes 
and inhibit PEPCK gene expression through a mecha- 
nism involving calcium influx into the cell, in addition 
to a mechanism dependent on protein kinase C 
[32,40,41]. 
The inhibition of the expression of the PEPCK gene 
observed in this study suggests that calcium-mobilizing 
agents, insulin and vanadate probably cause activation 
of calcium/calmodulin-dependent protein kinases. This 
kinase(s) might be able to modify a set of specific tran- 
scription factors involved in the regulation of this gene. 
However, further research is needed before the mecha- 
nism(s) involved in this process can be understood fully. 
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